Annexin Pharmaceuticals AB (publ) was established in 2014 and is a world-leading biotechnology company in the Annexin A5 field, for treatment of various cardiovascular diseases, which are currently the most common cause of death.
The Company’s development programme is based on an earlier discovery by Professor Johan Frostegård and Dr. Anna Frostegård at Karolinska Institutet in Stockholm, Sweden. The Company’s biological drug candidate ANXV – a human recombinant protein, Annexin A5 – is intended primarily for the acute treatment of patients with vascular diseases including vascular damages and inflammation.
ANXV has the ability to protect and repair the blood vessels as well as counteract the inflammation. ANXV is therefore expected to reduce suffering and hopefully mortality for several patient groups with both rare vascular diseases and major ones, such as heart attack.
ANXV has the potential to become a First-In-Class drug (a product with new and unique mechanisms of action which is the first of its kind on the market) for several patient groups where there is considerable unmet demand for medical treatment.
The Company also has a comprehensive patent portfolio for the treatment of diseases caused by vascular damage and inflammation. Annexin Pharmaceuticals has established and optimized a cell line for large-scale production of ANXV. The production process is patented.